{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T20:42:38Z","timestamp":1781210558587,"version":"3.54.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["RO1 AR073178"],"award-info":[{"award-number":["RO1 AR073178"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.rdc.2022.04.003","type":"journal-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T16:23:28Z","timestamp":1659975808000},"page":"659-678","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Treatment Guidelines in Gout"],"prefix":"10.1016","volume":"48","author":[{"given":"Allan C.","family":"Gelber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.rdc.2022.04.003_bib1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMcp1001124","article-title":"Clinical practice: gout","volume":"364","author":"Neogi","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.rdc.2022.04.003_bib2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/acr.21791","article-title":"Body mass index, obesity, and prevalent gout in the United States in 1988-1994 and 2007-2010","volume":"65","author":"Juraschek","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"10.1016\/j.rdc.2022.04.003_bib3","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41584-020-0441-1","article-title":"Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors","volume":"16","author":"Dehlin","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2022.04.003_bib4","doi-asserted-by":"crossref","first-page":"e56546","DOI":"10.1371\/journal.pone.0056546","article-title":"Dose-response association of uncontrolled blood pressure and cardiovascular disease risk factors with hyperuricemia and gout","volume":"8","author":"Juraschek","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.rdc.2022.04.003_bib5","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.semarthrit.2012.09.009","article-title":"Association of kidney disease with prevalent gout in the United States in 1988-1994 and 2007-2010","volume":"42","author":"Juraschek","year":"2013","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.rdc.2022.04.003_bib6","first-page":"2403","article-title":"Epidemiology of gout: is the incidence rising?","volume":"29","author":"Arromdee","year":"2002","journal-title":"J\u00a0Rheumatol"},{"issue":"23","key":"10.1016\/j.rdc.2022.04.003_bib7","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJM197112022852306","article-title":"Treatment of gout","volume":"285","author":"Goldfinger","year":"1971","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.rdc.2022.04.003_bib8","doi-asserted-by":"crossref","first-page":"229","DOI":"10.7326\/0003-4819-64-2-229","article-title":"Allopurinol in the treatment of gout","volume":"64","author":"Rundles","year":"1966","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.rdc.2022.04.003_bib9","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1056\/NEJM199602153340707","article-title":"The management of gout","volume":"334","author":"Emmerson","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"7081","key":"10.1016\/j.rdc.2022.04.003_bib10","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.rdc.2022.04.003_bib11","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1002\/art.27600","article-title":"Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study","volume":"62","author":"So","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.rdc.2022.04.003_bib12","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/ard.2009.108936","article-title":"The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study","volume":"68","author":"Terkeltaub","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.rdc.2022.04.003_bib13","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1136\/ard.2007.073759","article-title":"Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra","volume":"66","author":"McGonagle","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2022.04.003_bib14","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/art.22767","article-title":"Quality of care for gout in the US needs improvement","volume":"57","author":"Singh","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.rdc.2022.04.003_bib15","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1136\/annrheumdis-2012-201687","article-title":"Gout: why is this curable disease so seldom cured?","volume":"71","author":"Doherty","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2022.04.003_bib16","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/acr.22469","article-title":"Gout, urate-lowering therapy, and uric acid levels among adults in the United States","volume":"67","author":"Juraschek","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"10.1016\/j.rdc.2022.04.003_bib17","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/annrheumdis-2013-204463","article-title":"Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study","volume":"74","author":"Kuo","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2022.04.003_bib18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7326\/M16-0570","article-title":"Clinical Guidelines Committee of the American College of Physicians. Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.rdc.2022.04.003_bib19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2022.04.003_bib20","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"2020 American College of Rheumatology guideline for the management of gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"10.1016\/j.rdc.2022.04.003_bib21","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","article-title":"High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study","volume":"62","author":"Terkeltaub","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.rdc.2022.04.003_bib22","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.rdc.2022.04.003_bib23","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa035700","article-title":"Purine-rich foods, dairy and protein intake, and the risk of gout in men","volume":"350","author":"Choi","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.rdc.2022.04.003_bib24","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1001\/archinte.165.7.742","article-title":"Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study","volume":"165","author":"Choi","year":"2005","journal-title":"Arch Intern Med"},{"issue":"9417","key":"10.1016\/j.rdc.2022.04.003_bib25","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(04)16000-5","article-title":"Alcohol intake and risk of incident gout in men: a prospective study","volume":"363","author":"Choi","year":"2004","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.rdc.2022.04.003_bib26","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1001\/archinte.1997.00440340060005","article-title":"Gout and risk for subsequent coronary heart disease. The Meharry-Hopkins Study","volume":"157","author":"Gelber","year":"1997","journal-title":"Arch Intern Med"},{"issue":"14","key":"10.1016\/j.rdc.2022.04.003_bib27","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMc053668","article-title":"Febuxostat versus allopurinol for gout","volume":"354","author":"Gelber","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.rdc.2022.04.003_bib28","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.rdc.2022.04.003_bib29","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"10.1016\/j.rdc.2022.04.003_bib30","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"23","key":"10.1016\/j.rdc.2022.04.003_bib31","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.rdc.2022.04.003_bib32","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.rdc.2022.04.003_bib33","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/phar.2674","article-title":"A systematic review of the drug-drug interaction between statins and colchicine: Patient characteristics, etiologies, and clinical management strategies","volume":"42","author":"Schwier","year":"2022","journal-title":"Pharmacotherapy"},{"issue":"11","key":"10.1016\/j.rdc.2022.04.003_bib34","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B\u22175801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"5","key":"10.1016\/j.rdc.2022.04.003_bib35","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.semarthrit.2016.10.009","article-title":"The cost-effectiveness of HLA-B\u22175801 screening to guide initial urate-lowering therapy for gout in the United States","volume":"46","author":"Jutkowitz","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.rdc.2022.04.003_bib36","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1136\/annrheumdis-2017-212905","article-title":"Racial\/ethnic variation and risk factors for allopurinol-associated severe cutaneous adverse reactions: a cohort study","volume":"77","author":"Keller","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2022.04.003_bib37","doi-asserted-by":"crossref","first-page":"d8190","DOI":"10.1136\/bmj.d8190","article-title":"Antihypertensive drugs and risk of incident gout among patients with hypertension: population-based case-control study","volume":"344","author":"Choi","year":"2012","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.rdc.2022.04.003_bib38","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/acr.20519","article-title":"Effect of oral vitamin C supplementation on serum uric acid: a meta-analysis of randomized controlled trials","volume":"63","author":"Juraschek","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"10.1016\/j.rdc.2022.04.003_bib39","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1002\/art.34677","article-title":"Cherry consumption and decreased risk of recurrent gout attacks","volume":"64","author":"Zhang","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.rdc.2022.04.003_bib40","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1002\/art.34676","article-title":"If life serves up a bowl of cherries, and gout attacks are \"the pits\": implications for therapy","volume":"64","author":"Gelber","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2022.04.003_bib41","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/annrheumdis-2011-200156","article-title":"Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: a proof-of-concept randomised controlled trial","volume":"71","author":"Dalbeth","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2022.04.003_bib42","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/art.39527","article-title":"Effects of Lowering Glycemic Index of Dietary Carbohydrate on Plasma Uric Acid Levels: The OmniCarb Randomized Clinical Trial","volume":"68","author":"Juraschek","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.rdc.2022.04.003_bib43","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1002\/art.39813","article-title":"Effects of the Dietary Approaches to Stop Hypertension (DASH) Diet and Sodium Intake on Serum Uric Acid","volume":"68","author":"Juraschek","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2022.04.003_bib44","doi-asserted-by":"crossref","first-page":"j1794","DOI":"10.1136\/bmj.j1794","article-title":"The Dietary Approaches to Stop Hypertension (DASH) diet, Western diet, and risk of gout in men: prospective cohort study","volume":"357","author":"Rai","year":"2017","journal-title":"BMJ"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X22000382?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X22000382?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:29:06Z","timestamp":1760182146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X22000382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0889857X22000382"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2022.04.003","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Guidelines in Gout","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2022.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}